Hepatitis Monthly

Published by: Kowsar

A Real-Life Study of New Antiviral Therapies in a High Prevalence Geographical Area for Hepatitis C Virus Infection

Alessandro Federico 1 , * , Marcello Dallio 1 , Giuseppe Gerardo Caprio 1 , Ilario de Sio 1 , Gaetano Cotticelli 1 , Pasquale Esposito 1 and Carmelina Loguercio 1
Authors Information
1 Hepatogastroenterology Division, University of Campania "L. Vanvitelli", Naples, Italy
Article information
  • Hepatitis Monthly: October 2018, 18 (10); e74224
  • Published Online: October 15, 2018
  • Article Type: Research Article
  • Received: May 2, 2018
  • Revised: August 11, 2018
  • Accepted: August 13, 2018
  • DOI: 10.5812/hepatmon.74224

To Cite: Federico A, Dallio M, Caprio G G, de Sio I, Cotticelli G, et al. A Real-Life Study of New Antiviral Therapies in a High Prevalence Geographical Area for Hepatitis C Virus Infection, Hepat Mon. 2018 ; 18(10):e74224. doi: 10.5812/hepatmon.74224.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-76. doi: 10.1016/S2468-1253(16)30181-9. [PubMed: 28404132].
  • 2. European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: A modelling study. Lancet Gastroenterol Hepatol. 2017;2(5):325-36. doi: 10.1016/S2468-1253(17)30045-6. [PubMed: 28397696].
  • 3. La Torre G, Gualano MR, Semyonov L, Nicolotti N, Ricciardi W, Boccia A. Hepatitis C Virus infections trends in Italy, 1996-2006. Hepat Mon. 2011;11(11):895-900. doi: 10.5812/kowsar.1735143X.767. [PubMed: 22308154]. [PubMed Central: PMC3269058].
  • 4. Marascio N, Liberto M, Barreca G, Zicca E, Quirino A, Lamberti A, et al. Update on epidemiology of HCV in Italy: Focus on the Calabria Region. BMC Infect Dis. 2014;14 Suppl 5. S2. doi: 10.1186/1471-2334-14-S5-S2. [PubMed: 25236184]. [PubMed Central: PMC4160896].
  • 5. Mennini FS, Marcellusi A, Andreoni M, Gasbarrini A, Salomone S, Craxi A. Health policy model: Long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. Clinicoecon Outcomes Res. 2014;6:303-10. doi: 10.2147/CEOR.S62092. [PubMed: 24971024]. [PubMed Central: PMC4069043].
  • 6. Perrone V, Sangiorgi D, Buda S, Degli Esposti L. Disease progression and health care resource consumption in patients affected by hepatitis C virus in real practice setting. Clinicoecon Outcomes Res. 2016;8:591-7. doi: 10.2147/CEOR.S108288. [PubMed: 27789966]. [PubMed Central: PMC5072570].
  • 7. Buonomo AR, Scotto R, Pinchera B, Coppola N, Monari C, Macera M, et al. Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy. New Microbiol. 2018;41(1):26-9. [PubMed: 29112765].
  • 8. Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of Pegylated Interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: A meta-analysis. BMC Infect Dis. 2012;12:357. doi: 10.1186/1471-2334-12-357. [PubMed: 23245594]. [PubMed Central: PMC3556138].
  • 9. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49(4):1335-74. doi: 10.1002/hep.22759. [PubMed: 19330875].
  • 10. Loguercio C, Federico A, Masarone M, Torella R, Blanco Cdel V, Persico M. The impact of diet on liver fibrosis and on response to Interferon therapy in patients with HCV-related chronic hepatitis. Am J Gastroenterol. 2008;103(12):3159-66. doi: 10.1111/j.1572-0241.2008.02159.x. [PubMed: 18786125].
  • 11. Federico A, Masarone M, Romano M, Dallio M, Rosato V, Persico M. Rapid virological response represents the highest prediction factor of response to antiviral treatment in HCV-related chronic hepatitis: A multicenter retrospective study. Hepat Mon. 2015;15(6). e18640. doi: 10.5812/hepatmon.15(6)2015.18640. [PubMed: 26286149]. [PubMed Central: PMC4532787].
  • 12. Poordad F, McCone JJ, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-206. doi: 10.1056/NEJMoa1010494. [PubMed: 21449783]. [PubMed Central: PMC3766849].
  • 13. Federico A, Sgambato D, Cotticelli G, Gravina AG, Dallio M, Beneduce F, et al. Skin adverse events during dual and triple therapy for HCV-related cirrhosis. Hepat Mon. 2014;14(3). e16632. doi: 10.5812/hepatmon.16632. [PubMed: 24734094]. [PubMed Central: PMC3984470].
  • 14. European Association for Study of Liver. EASL clinical practice guidelines: Management of hepatitis C virus infection. J Hepatol. 2014;60(2):392-420. doi: 10.1016/j.jhep.2013.11.003. [PubMed: 24331294].
  • 15. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-77. doi: 10.1056/NEJMoa1214854. [PubMed: 23607593].
  • 16. Kondili LA, Romano F, Rolli FR, Ruggeri M, Rosato S, Brunetto MR, et al. Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. Hepatology. 2017;66(6):1814-25. doi: 10.1002/hep.29399. [PubMed: 28741307]. [PubMed Central: PMC5765396].
  • 17. Grimaldi E, Della Pepa ME, Martora F, Magliocca P, Iovene MR, Coppola N, et al. Distribution of hepatitis C virus genotypes and subtypes in the metropolitan area of naples, Italy, in the era of Interferon-free regimens. Intervirol. 2017;60(3):82-9. doi: 10.1159/000481821. [PubMed: 29161710].
  • 18. Hutchison C, Kwong A, Ray S, Struble K, Swan T, Miller V. Accelerating drug development through collaboration: The Hepatitis C Drug Development Advisory Group. Clin Pharmacol Ther. 2014;96(2):162-5. doi: 10.1038/clpt.2014.113. [PubMed: 24853733].
  • 19. Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, et al. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatol. 2015;62(5):1623-32. doi: 10.1002/hep.27934. [PubMed: 26095927].
  • 20. European Association for Study of L. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. [PubMed: 25911336].
  • 21. Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer. 2015;121(17):2874-82. doi: 10.1002/cncr.29528. [PubMed: 26079399]. [PubMed Central: PMC4545677].
  • 22. Scott N, Stoove M, Wilson DP, Keiser O, El-Hayek C, Doyle J, et al. Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: A multi-modelling approach to understand differences in sexual risk behaviour. J Int AIDS Soc. 2018;21(1). doi: 10.1002/jia2.25059. [PubMed: 29314670]. [PubMed Central: PMC5810343].
  • 23. Asselah T, Marcellin P, Schinazi RF. Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver Int. 2018;38 Suppl 1:7-13. doi: 10.1111/liv.13673. [PubMed: 29427484].
  • 24. Cooper CL, Hatashita H, Corsi DJ, Parmar P, Corrin R, Garber G. Direct-acting antiviral therapy outcomes in canadian chronic hepatitis C telemedicine patients. Ann Hepatol. 2017;16(6):874-80. doi: 10.5604/01.3001.0010.5277. [PubMed: 29055923].
  • 25. Monllor-Nunell MT, Sanchez-Lloansi M, Dosal-Galguera A. Direct antiviral treatment in patients with hepatitis C virus: Implementation of a nurse telephone consultation. Enferm Clin. 2017;27(6):387-91. doi: 10.1016/j.enfcli.2017.09.005. [PubMed: 29074167].
  • 26. Lawitz E, Makara M, Akarca US, Thuluvath PJ, Preotescu LL, Varunok P, et al. Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterol. 2015;149(4):971-80 e1. doi: 10.1053/j.gastro.2015.07.001. [PubMed: 26170136].
  • 27. Roeder C, Jordan S, Schulze Zur Wiesch J, Pfeiffer-Vornkahl H, Hueppe D, Mauss S, et al. Age-related differences in response to peginterferon alfa-2a/Ribavirin in patients with chronic hepatitis C infection. World J Gastroenterol. 2014;20(31):10984-93. doi: 10.3748/wjg.v20.i31.10984. [PubMed: 25152602]. [PubMed Central: PMC4138479].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments